<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05613686</url>
  </required_header>
  <id_info>
    <org_study_id>202204105DINB</org_study_id>
    <nct_id>NCT05613686</nct_id>
  </id_info>
  <brief_title>Theta Burst Stimulation for Motor Recovery</brief_title>
  <official_title>Comparative Efficacy of Different Doses of Theta Burst Stimulation for Motor Recovery in Stroke Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation&#xD;
      technology. This study will compare efficacy of different doses iTBS in combination with&#xD;
      inhibitory rTMS on motor recovery and cortical excitability in subacute stroke patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation&#xD;
      technology.&#xD;
&#xD;
      High and low frequencies of rTMS could modulate the excitability of the cerebral cortex.&#xD;
      Theta burst stimulation (TBS) has achieved a similar effect to traditional rTMS mode.&#xD;
      Intermittent TBS (iTBS) could upregulate cortical excitability of the primary motor cortex&#xD;
      (M1) and continuous TBS (cTBS) with inhibitory effect. Through modulating the excitability of&#xD;
      bilateral hemispheres, rTMS could facilitate motor recovery in stroke patients.&#xD;
&#xD;
      This study will compare efficacy of different doses iTBS in combination with inhibitory rTMS&#xD;
      on motor recovery and cortical excitability in subacute stroke patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2022</start_date>
  <completion_date type="Anticipated">October 29, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 29, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fugl-Meyer Assessment</measure>
    <time_frame>12 weeks post intervention</time_frame>
    <description>Fugl-Meyer Assessment motor function set, score: 0-66, higher scores indicate a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medical Research Council (MRC) Scale for Muscle Strength</measure>
    <time_frame>1 week, 4 weeks, 12 weeks and 24 weeks post intervention</time_frame>
    <description>Medical Research Council (MRC) Scale for Muscle Strength, assessing muscle strength from Grade 5 (normal) to Grade 0 (no visible contraction).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institutes of Health Stroke Scale</measure>
    <time_frame>1 week, 4 weeks, 12 weeks and 24 weeks post intervention</time_frame>
    <description>National Institutes of Health Stroke Scale, The maximum possible score is 42, with the minimum score being a 0. Higher scores indicate a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index</measure>
    <time_frame>1 week, 4 weeks, 12 weeks and 24 weeks post intervention</time_frame>
    <description>Barthel Index, score 100-0. Higher scores indicate a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale</measure>
    <time_frame>1 week, 4 weeks, 12 weeks and 24 weeks post intervention</time_frame>
    <description>Modified Rankin Scale, score from 0 to 6. Higher scores indicate a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MEP</measure>
    <time_frame>1 week, 4 weeks, 12 weeks and 24 weeks post intervention</time_frame>
    <description>motor evoked potential</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fugl-Meyer Assessment</measure>
    <time_frame>1 week post intervention</time_frame>
    <description>Fugl-Meyer Assessment motor function set, score: 0-66, higher scores indicate a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fugl-Meyer Assessment</measure>
    <time_frame>4 weeks post intervention</time_frame>
    <description>Fugl-Meyer Assessment motor function set, score: 0-66, higher scores indicate a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fugl-Meyer Assessment</measure>
    <time_frame>24 weeks post intervention</time_frame>
    <description>Fugl-Meyer Assessment motor function set, score: 0-66, higher scores indicate a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Transcranial Magnetic Stimulation</condition>
  <arm_group>
    <arm_group_label>contralateral 1Hz+ipsilateral iTBS 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received contralateral 1 Hz and ipsilateral iTBS with protocol 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>contralateral 1Hz+ipsilateral iTBS 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received contralateral 1 Hz and ipsilateral iTBS with protocol 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>contralateral 1Hz</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received contralateral 1 Hz and ipsilateral sham iTBS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>repetitive transcranial magnetic stimulation</intervention_name>
    <description>Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technology. High and low frequencies of rTMS could modulate the excitability of the cerebral cortex. Theta burst stimulation (TBS) has achieved a similar effect to traditional rTMS mode. Intermittent TBS (iTBS) could upregulate cortical excitability of the primary motor cortex (M1) and continuous TBS (cTBS) with inhibitory effect.</description>
    <arm_group_label>contralateral 1Hz</arm_group_label>
    <arm_group_label>contralateral 1Hz+ipsilateral iTBS 1</arm_group_label>
    <arm_group_label>contralateral 1Hz+ipsilateral iTBS 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.Unilateral ischemic or hemorrhagic stroke&#xD;
&#xD;
          -  2.Stroke within 3 months&#xD;
&#xD;
          -  3.Medical Research Council Scale for Muscle Strength in upper limb â‰¤ 3&#xD;
&#xD;
          -  4.No previous stroke, seizure, dementia, Parkinson's disease or other degenerative&#xD;
             neurological diseases.&#xD;
&#xD;
          -  5.Patient could sit over 15 minutes&#xD;
&#xD;
          -  6.Age over 20&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.Previous stroke, traumatic brain injury, brain tumor&#xD;
&#xD;
          -  2.With central nervous system disease (spinal cord injury, Parkinson's disease)&#xD;
&#xD;
          -  3.Any contraindication to rTMS (seizure, alcoholism, metal implant, pacemaker)&#xD;
&#xD;
          -  4.Patients unable to cooperate the treatment&#xD;
&#xD;
          -  5.Pregnancy&#xD;
&#xD;
          -  6.Depression&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meng Ting Lin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meng Ting Lin, M.D.</last_name>
    <phone>+886-2312-3456</phone>
    <phone_ext>67048</phone_ext>
    <email>b96401093@ntu.edu.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ming Yen Hsiao, M.D., PhD</last_name>
    <phone>+886-2312-3456</phone>
    <phone_ext>67316</phone_ext>
    <email>myferrant@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meng Ting Lin, M.D.</last_name>
      <phone>+886-2312-3456</phone>
      <email>b96401093@ntu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Lefaucheur JP, Aleman A, Baeken C, Benninger DH, Brunelin J, Di Lazzaro V, Filipovic SR, Grefkes C, Hasan A, Hummel FC, Jaaskelainen SK, Langguth B, Leocani L, Londero A, Nardone R, Nguyen JP, Nyffeler T, Oliveira-Maia AJ, Oliviero A, Padberg F, Palm U, Paulus W, Poulet E, Quartarone A, Rachid F, Rektorova I, Rossi S, Sahlsten H, Schecklmann M, Szekely D, Ziemann U. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). Clin Neurophysiol. 2020 Feb;131(2):474-528. doi: 10.1016/j.clinph.2019.11.002. Epub 2020 Jan 1. Erratum In: Clin Neurophysiol. 2020 May;131(5):1168-1169.</citation>
    <PMID>31901449</PMID>
  </reference>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>October 30, 2022</study_first_submitted>
  <study_first_submitted_qc>November 6, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>November 6, 2022</last_update_submitted>
  <last_update_submitted_qc>November 6, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>will make further analysis</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

